Updated recommendations for the treatment of rheumatoid arthritis: Another step on a long road

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Arthritis care & research

• Publication date

  2012-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/acr.21659PMID 22473919PMCID PMC4097090
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice

  2012cited by this paper
• Observational studies on the risk of cancer associated with tumor necrosis factor inhibitors in rheumatoid arthritis: a review of their methodologies and results.

  2012cited by this paper
• 2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease‐modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis

  2012cited by this paper
• Observational Studies on the Risk of Cancer Associated With Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: A Review of Their Methodologies and Results

  2012cited by this paper
• 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/ SCAI/SIR/SNIS/SVM/SVS Guideline on the Management of Patients With Extracranial Carotid and Vertebral Artery Disease: Executive Summary

  2011cited by this paper
• Hepatosplenic T-cell lymphoma in patients receiving TNF-&agr; inhibitor therapy: expanding the groups at risk

  2011cited by this paper
• Does cancer that occurs during or after anti-tumor necrosis factor therapy have a worse prognosis? A national assessment of overall and site-specific cancer survival in rheumatoid arthritis patients treated with biologic agents.

  2011cited by this paper
• American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.

  2008cited by this paper
• GRADE: an emerging consensus on rating quality of evidence and strength of recommendations

  2008cited by this paper
• Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease.

  2007cited by this paper
• The Appropriateness Method

  2004cited by this paper
• American College of Rheumatology 2008 Recommendations for the Use of Nonbiologic and Biologic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis

  year unknowncited by this paper

• Safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of WBP216, a novel IL-6 monoclonal antibody, in patients with rheumatoid arthritis: A phase Ia randomized placebo-controlled study

  2023cites this paper
• Rituximab as a treatment option in a patient with rheumatoid arthritis and a history of malignancy—intracranial chondrosarcoma/osteochondroma—case based review

  2020cites this paper
• DEK-targeting DNA aptamers as therapeutics for inflammatory arthritis

  2017cites this paper
• Efficacy and safety of monoclonal antibodies targeting interleukin-17 pathway for inflammatory arthritis: a meta-analysis of randomized controlled clinical trials

  2016cites this paper
• Efficacy and safety of monoclonal antibodies targeting interleukin-17 pathway for inflammatory arthritis: a meta-analysis of randomized controlled clinical trials

  2016cites this paper
• Efficacy and safety of monoclonal antibodies targeting interleukin-17 pathway for inflammatory arthritis: a meta-analysis of randomized controlled clinical trials

  2016cites this paper
• The role of autoreactive T cell in the pathogenesis of rheumatoid arthritis and implications for T cell targeted vaccine therapy.

  2015cites this paper
• Variations and Practice in the Care of Patients With Rheumatoid Arthritis: Quality and Cost of Care

  2014cites this paper
• Targeting inflammation and wound healing by opioids.

  2013cites this paper
• A phase Ib multiple ascending dose study evaluating safety, pharmacokinetics, and early clinical response of brodalumab, a human anti-IL-17R antibody, in methotrexate-resistant rheumatoid arthritis

  2013cites this paper
• Involvement of Multiple Transporters-mediated Transports in Mizoribine and Methotrexate Pharmacokinetics

  2012cites this paper